厄洛替尼治疗期间皮肤副作用:病例报告

Q4 Medicine

Scripta Medica Pub Date : 2021-01-01 DOI:10.5937/scriptamed52-35385

S. Jovičić, Vesna Gajanin, Sanja Umičević-Šipka

{"title":"厄洛替尼治疗期间皮肤副作用:病例报告","authors":"S. Jovičić, Vesna Gajanin, Sanja Umičević-Šipka","doi":"10.5937/scriptamed52-35385","DOIUrl":null,"url":null,"abstract":"Erlotinib is an antineoplastic drug used in the treatment of non-small cell lung cancer and pancreatic cancer. It is a potent, selective inhibitor of tyrosine kinase, a receptor for epidermal growth factor receptor (EGFR). Cutaneous side effects such as acneiform eruption, xerosis, telangiectasia, hair and nail changes are common. A case of a 70-year-old patient who developed unusual cutaneous side effects after 6 years of treatment with erlotinib was presented.","PeriodicalId":33497,"journal":{"name":"Scripta Medica","volume":"29 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Cutaneous side effects during therapy with Erlotinib: Case report\",\"authors\":\"S. Jovičić, Vesna Gajanin, Sanja Umičević-Šipka\",\"doi\":\"10.5937/scriptamed52-35385\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Erlotinib is an antineoplastic drug used in the treatment of non-small cell lung cancer and pancreatic cancer. It is a potent, selective inhibitor of tyrosine kinase, a receptor for epidermal growth factor receptor (EGFR). Cutaneous side effects such as acneiform eruption, xerosis, telangiectasia, hair and nail changes are common. A case of a 70-year-old patient who developed unusual cutaneous side effects after 6 years of treatment with erlotinib was presented.\",\"PeriodicalId\":33497,\"journal\":{\"name\":\"Scripta Medica\",\"volume\":\"29 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Scripta Medica\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5937/scriptamed52-35385\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Scripta Medica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5937/scriptamed52-35385","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

厄洛替尼是一种用于治疗非小细胞肺癌和胰腺癌的抗肿瘤药物。它是一种有效的选择性酪氨酸激酶抑制剂，酪氨酸激酶是表皮生长因子受体(EGFR)的受体。皮肤的副作用，如痤疮疹，干燥，毛细血管扩张，头发和指甲的变化是常见的。一个病例70岁的病人谁发展了不寻常的皮肤副作用后6年治疗厄洛替尼提出。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Cutaneous side effects during therapy with Erlotinib: Case report

Erlotinib is an antineoplastic drug used in the treatment of non-small cell lung cancer and pancreatic cancer. It is a potent, selective inhibitor of tyrosine kinase, a receptor for epidermal growth factor receptor (EGFR). Cutaneous side effects such as acneiform eruption, xerosis, telangiectasia, hair and nail changes are common. A case of a 70-year-old patient who developed unusual cutaneous side effects after 6 years of treatment with erlotinib was presented.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Scripta Medica

CiteScore

0.60

自引率

0.00%

发文量

审稿时长

4 weeks